MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Search

CorMedix Inc

Cerrado

SectorSanidad

6.86 1.33

Resumen

Variación precio

24h

Actual

Mínimo

6.54

Máximo

6.89

Métricas clave

By Trading Economics

Ingresos

89M

109M

Ventas

65M

104M

P/B

Media del Sector

3.068

90.831

Margen de beneficios

104.112

Empleados

64

EBITDA

37M

57M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+161.8% upside

Dividendos

By Dow Jones

Próximas Ganancias

24 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-334M

534M

Apertura anterior

5.53

Cierre anterior

6.86

Noticias sobre sentimiento de mercado

By Acuity

55%

45%

297 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Consolidates; May Face Technical Correction -- Market Talk

20 ene 2026, 23:42 UTC

Charlas de Mercado

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 ene 2026, 23:41 UTC

Ganancias

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 ene 2026, 23:29 UTC

Charlas de Mercado

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 ene 2026, 23:26 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 ene 2026, 23:26 UTC

Charlas de Mercado

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 ene 2026, 22:45 UTC

Adquisiciones, fusiones, absorciones

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 ene 2026, 22:45 UTC

Adquisiciones, fusiones, absorciones

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 ene 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 ene 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 ene 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 ene 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 ene 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 ene 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 ene 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 ene 2026, 22:18 UTC

Ganancias

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 ene 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 ene 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 ene 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 ene 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 ene 2026, 22:13 UTC

Adquisiciones, fusiones, absorciones

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 ene 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 ene 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 ene 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 ene 2026, 22:07 UTC

Adquisiciones, fusiones, absorciones

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 ene 2026, 22:06 UTC

Ganancias

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 ene 2026, 22:00 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

ESG Roundup: Market Talk

20 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

161.8% repunte

Estimación a 12 Meses

Media 17.75 USD  161.8%

Máximo 22 USD

Mínimo 15 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

297 / 361 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat